Product Description: BI-3406 (compound I-6) is an orally active, highly potent and selective inhibitor of the interaction between KRAS and Son of Sevenless 1 (SOS1) with an IC50 of 6 nM. BI-3406 potently reduces the formation of GTP-loaded KRAS, and inhibits MAPK pathway signaling. BI-3406 has anticancer activity[1][2].
Applications: Cancer-Kinase/protease
Formula: C23H25F3N4O3
References: [1]Michael Gmachl, et al. Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors. WO2018115380A1./[2]Marco H Hofmann, et al. Abstract PL06-01: Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors. December 2019.
CAS Number: 2230836-55-0
Molecular Weight: 462.46
Compound Purity: 99.95
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)/Ethanol : 100 mg/mL (ultrasonic)
Target: p38 MAPK;Ras
Deutsch
English
